Innate Pharma announces FDA lifts clinical hold on lacutamab IND

Innate Pharma announced that the FDA has lifted the partial clinical hold placed on the lacutamab IND. On October 5, Innate announced that the lacutamab IND has been placed on partial clinical hold by FDA following a recent patient death in the TELLOMAK study. The death of a patient affected by Sezary syndrome was initially considered due to hemophagocytic lymphohistiocytosis, a rare hematologic disorder. The FDA decision to lift the partial clinical hold is based on the FDA review of the fatal case which Innate, together with a steering committee of independent experts, determined to be related to aggressive disease progression and lacutamab unrelated.